ClinicalTrials.gg
CompletedNCT00935259Updated Oct 8, 2015Results posted

Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)

A Phase 1 interventional study of Simvastatin and Placebo in Hypercholesterolemia, Dyslipidemia, sponsored by Merck Sharp & Dohme LLC. Completed. Open to male participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-10-08.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
30 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing simvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. Simvastatin · Hypercholesterolemia.

Enrollment
38th of 49
31 · median 240
Started
2009
with 1 other
Phase 1
2 of 50
none open now
Registered
38th of 50
by date
Lead sponsor
3 of 50
Merck Sharp & Dohme LLC

Among the 50 studies testing simvastatin in Hypercholesterolemia, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 1, and was the 38th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 50 studies testing simvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About simvastatin

Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 30 Years to 70 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing simvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study was to provide human lipidomics standards with simvastatin treatment that were to be used for comparison with similar preclinical studies.

03

Conditions studied

  • Hypercholesterolemia, Dyslipidemia

Keywords

  • Hypercholesterolemia, Dyslipidemia, simvastatin, Zocor
04

Who can participate

Ages eligible
30 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a Caucasian (including Hispanic) male
  • Participant has a maximum waist size of 40 inches
  • Participant does not currently use any lipid-altering medications
  • Participant is in good health other than the diagnosis of dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Participant has had stomach ulcers within the last 3 months
  • Participant has had a heart attack in the last 6 months or has angina
  • Participant has chronic heart failure
  • Participant has a history of stroke, seizures, or major neurological disorder
  • Participant has a history of cancer
  • Participant has a gastrointestinal condition that affects bowel movements
  • Participant has type 1 or 2 diabetes
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Simvastatin 40 mg first, then placebo

    Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks

    Drug: Simvastatin · Drug: Placebo

  • Placebo comparator
    Placebo first, then simvastatin 40 mg once daily

    Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks

    Drug: Simvastatin · Drug: Placebo

Interventions

  • 40 mg once daily for 2 weeks

    Also known as: Zocor

  • DrugPlacebo

    Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks

06

What researchers measure

Primary outcomes

  1. Arachidonic Acid Level After 2 Weeks of Treatment

    Arachidonic acid level (20:4n6) in the cholesterol ester lipid class. The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.

    Time frame: 2 weeks

Secondary outcomes

  1. Fasting Blood Lipidomic Levels After 2 Weeks of Treatment

    Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo. The mean reported was an adjusted mean.

    Time frame: 2 weeks

  2. Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level

    Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio \[dose = 162 g/m\^2\]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion. The mean reported was an adjusted mean (defined in first outcome measure).

    Time frame: 2 weeks

  3. Blood Linoleic Acid Levels

    Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.

    Time frame: 2 weeks

  4. Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo

    Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.

    Time frame: 2 weeks

07

Results

Posted Feb 20, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneSimvastatin 40 mg, Then PlaceboPlacebo First, Then Simvastatin 40 mg
Started1615
Completed1514
Not completed11
Withdrew: Administrative (scheduling conflict)11
Period 2
Participant flow — Period 2
MilestoneSimvastatin 40 mg, Then PlaceboPlacebo First, Then Simvastatin 40 mg
Started1514
Completed1514
Not completed00

Outcome measures

PrimaryArachidonic Acid Level After 2 Weeks of Treatment

Arachidonic acid level (20:4n6) in the cholesterol ester lipid class. The mean reported was an adjusted mean, which was obtained from running a 2-period crossover model that had fixed treatment and period terms and a random participant term.

Time frame:
2 weeks
Reported as:
Mean · nmol
Arachidonic Acid Level After 2 Weeks of Treatment
nmolSimvastatin 40 mgPlacebo
Arachidonic Acid Level After 2 Weeks of Treatment259.1 ± 89.1269.6 ± 85.2
Statistical analysis
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.455 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -10.4An unstructured covariance and Kenward Roger degrees of freedom were assumed.
SecondaryFasting Blood Lipidomic Levels After 2 Weeks of Treatment

Change in fasting blood cholesterol ester, lysophosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine, and triacylglycerol levels compared to placebo. The mean reported was an adjusted mean.

Time frame:
2 weeks
Reported as:
Mean · nmol
Fasting Blood Lipidomic Levels After 2 Weeks of Treatment
nmolSimvastatin 40 mgPlacebo
Cholesterol ester lipid 16:00288.9 ± 102.1345.1 ± 87.3
Cholesterol ester lipid 18:3n310.0 ± 4.814.4 ± 6.7
Cholesterol ester lipid 20:3n620.9 ± 10.523.5 ± 10.2
Cholesterol ester lipid 20:3n91.3 ± 1.11.2 ± 0.9
Cholesterol ester lipid 22:5n61.0 ± 0.81.1 ± 0.4
Cholesterol ester lipid 22:6n312.7 ± 5.114.8 ± 6.8
Lysophosphatidyl-choline lipid 20:4n611.1 ± 3.810.3 ± 2.7
Phosphatidyl-choline lipid 18:2n6684.8 ± 224.9824.9 ± 196.2
Phosphatidyl-choline lipid 20:3n6117.4 ± 54.3127.1 ± 58.8
Phosphatidyl-choline lipid 20:4n6458.0 ± 138.4443.2 ± 98.1
Phosphatidyl-choline lipid 22:5n330.3 ± 10.234.3 ± 12.8
Phosphatidyl-choline lipid 22:5n611.4 ± 6.412.1 ± 4.1
Phosphatidyl-ethanolamine lipid 18:2n621.8 ± 9.332.1 ± 15.5
Triacylglycerol 16:00788.3 ± 431.61005.1 ± 662.2
Triacylglycerol 20:3n94.5 ± 5.54.9 ± 2.8
Statistical analysis
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.014 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -51.7An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = <0.001 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -4.5An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.217 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -2.5An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.666 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 0.1An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.776 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 0.0An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.018 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -2.5An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.152 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 1.1An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.007 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -132.1An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.325 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -11.8An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.419 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 18.3An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.070 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -4.7An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.769 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -0.2An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = <0.001 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -11.1An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.016 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): -240.8An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.833 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 0.1An unstructured covariance and Kenward Roger degrees of freedom were assumed.
SecondarySerum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level

Two days of standardized, pre-packaged meals were provided prior to the 10-hour fast required before blood collection. To assess how consumption of a meal would affect levels of plasma PCSK9, following each of the fasting blood draws, participants were asked to consume a high fat meal (heavy whipping cream + vanilla ice cream in a 1:4 ratio \[dose = 162 g/m\^2\]) within 20 minutes. For the duration of the test, participants were to remain seated or recumbent until blood samples were drawn 4 h after meal completion. The mean reported was an adjusted mean (defined in first outcome measure).

Time frame:
2 weeks
Reported as:
Mean · nmol
Serum Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) Level
nmolSimvastatin 40 mgPlacebo
Fed6.06 ± 2.344.69 ± 1.66
Fasted6.47 ± 2.115.51 ± 1.91
Statistical analysis
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.027 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 0.90An unstructured covariance and Kenward Roger degrees of freedom were assumed.
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = <0.001 (Endpoint was analyzed as appropriate for a 2-period crossover model using a mixed model with fixed terms of period and treatment with participants as a random factor.) · Mean difference (final values): 1.40An unstructured covariance and Kenward Roger degrees of freedom were assumed.
SecondaryBlood Linoleic Acid Levels

Change in blood linoleic acid levels for Cholesterol Ester compared to placebo.

Time frame:
2 weeks
Reported as:
Mean · nmol
Blood Linoleic Acid Levels
nmolSimvastatin 40 mgPlacebo
Blood Linoleic Acid Levels1184.7 ± 393.41504.7 ± 327.8
SecondaryChange in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo

Change in fasting delta 5 desaturase enzyme activity compared to placebo. Delta 5 desaturase enzyme activity is defined as the ratios of C20:4n-6 to C20:3n-6 and C20:5n-3 to C20:4n-3.

Time frame:
2 weeks
Reported as:
Mean · ratio
Change in Fasting Delta 5 Desaturase Enzyme Activity Compared to Placebo
ratioSimvastatin 40 mgPlacebo
Cholesterol ester c20:4n6 / c20:3n612.2234 ± 3.41311.5662 ± 3.684
Cholesterol Ester c20:5n3/c20:4n317.9161 ± 7.73816.3024 ± 9.465
Statistical analysis
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.247
  • Simvastatin 40 mg vs Placebo · Mixed Models Analysis · p = 0.151

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Simvastatin—0/30 (0%)1/30 (3.3%)
Placebo—0/30 (0%)2/30 (6.7%)
Most frequent other events
Most frequent other events
EventSimvastatinPlacebo
Tension headacheNervous system disorders1/301/30
DiarrhoeaGastrointestinal disorders0/301/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years31
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female0
Male31
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Chen F, Maridakis V, O'Neill EA, Hubbard BK, Strack A, Beals C, Herman GA, Wong P. The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia. Biomarkers. 2011 Jun;16(4):321-33. doi: 10.3109/1354750X.2011.561367. Epub 2011 Mar 21. PubMed 21417623 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2009
First posted
Jul 8, 2009
Start
Jul 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Feb 20, 2012
Last update
Oct 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00935259
Responsible party
Sponsor
First posted
Jul 8, 2009
Start date
Jul 2009
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Feb 20, 2012
Last update
Oct 8, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simvastatin

Start the discussion